Gleevec Maker Immune From Antitrust Liability, 1st Circuit Affirms
BOSTON — Allegations by two putative classes that Novartis Pharmaceuticals Corp. fraudulently procured a patent for the leukemia drug Gleevec are not plausible, and the drug maker thus cannot be subject...To view the full article, register now.
Already a subscriber? Click here to view full article